Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease.

BMC gastroenterology - 13 Apr 2026

Fteah Asmaa Mohamed, Aly Doaa Mamdouh, Elrefaiy Mohamed A, Rahim Ali Abdel

Abstract excerpt

BACKGROUND & AIMS: Interindividual variability in metabolic dysfunction–associated steatotic liver disease (MASLD) onset and its progressive inflammatory stage, metabolic dysfunction–associated steatohepatitis (MASH), reflects a complex interplay between metabolic burden and inherited susceptibility. We investigated the combined impact of genetic variants in the glucokinase regulatory protein gene (GCKR) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Fatty Liver

Share to Fibroblast Growth Factors

Share to Non-alcoholic Fatty Liver Disease

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 41975319
DOI: 10.1186/s12876-026-04767-9
PMCID: PMC13072530

Genes

FGF21
GCKR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GCKR genetic variants and circulating FGF21 identify a metabolic risk signature in metabolic dysfunction-associated steatotic liver disease.PMID 41975319Read ↗

GCKR genetic variants and circulating FGF21 define a metabolic risk signature in Metabolic-associated Steatotic Liver diseaseSemantic proximity Read ↗

Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism.Semantic proximity Read ↗

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity Read ↗

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.Semantic proximity Read ↗

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.Semantic proximity Read ↗

Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver BiomarkersSemantic proximity Read ↗

Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?Semantic proximity Read ↗

Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.Semantic proximity Read ↗

Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver DiseaseSemantic proximity Read ↗

Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.